Combating Alzheimer Disease by multitarget pyridinylidene hydrazones
It was surprisingly found that the pyridinylidene hydrazone derivatives inhibit AChE and BuChE as well as Aβ fibril formation significantly. They can destroy already formed fibrils. And they are able to cross the blood-brain barrier which is thought to be due to their pKa values and lipophilicity.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Roadmap to close the carbon cycle
A holistic approach to reach net-zero carbon emissions across the economy. A major approach to achieving net-zero carbon emissions relies on converting various parts of the economy, such as personal…
Cost-effective, high-capacity, and cyclable lithium-ion battery cathodes
Charge-recharge cycling of lithium-superrich iron oxide, a cost-effective and high-capacity cathode for new-generation lithium-ion batteries, can be greatly improved by doping with readily available mineral elements. The energy capacity and…
New regulator of eating behaviour identified
The rapidly escalating prevalence of overweight and obesity poses a significant medical challenge worldwide. In addition to people’s changing lifestyles, genetic factors also play a key role in the development…
